Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLYM116 in Healthy Volunteers
NCT07248865Phase 1Recruiting
- Sponsor
- Climb Bio
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CLYM116 in IgA nephropathy (IgAN) and systemic lupus erythematosus (SLE), sponsored by Climb Bio. Primary endpoints: Treatment-Emergent Adverse Events at Day 85 and Incidence of injection site reactions. Started Dec 2025; status: recruiting.
02
Drugs
CLYM116
03
Conditions
IgA nephropathy (IgAN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07248865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248865.